OVERVIEW OF ACTIVITY

Colorectal cancer is among the most common types of cancer in the United States, and management strategies are continuously evolving. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents, novel biomarkers affecting treatment selection and alterations to existing management algorithms. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, Colorectal Cancer Update utilizes one-on-one discussions with leading oncology investigators. By providing access to the latest research developments and expert perspectives, this CME activity assists medical oncologists with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Recall the ongoing clinical trials evaluating the addition of biologic agents to conventional adjuvant chemotherapy as treatment for Stage II and Stage III colon cancer.
• Utilize biomarkers to predict response or resistance to chemotherapy and/or biologic agents in patients with colorectal cancer (CRC).
• Develop up-to-date clinical management strategies for metastatic CRC, incorporating chemotherapy, VEGF inhibitors and EGFR inhibitors.
• Assess the application of recently reported and ongoing clinical trials evaluating tyrosine kinase inhibitors or the combination of EGFR and VEGF inhibition for patients with CRC.
• Counsel patients about the potential risk of oxaliplatin-induced neurotoxicity and the preventive measures that may offset its occurrence.
• Formulate a treatment plan for patients with synchronous or metachronous liver-only CRC metastases.
• Assess appropriate patients with CRC for eligibility in ongoing clinical trials.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains audio and print components. To receive credit, the participant should review the CME information, listen to the audio and complete the Post-test and Educational Assessment and Credit Form located on our website at ResearchToPractice.com/CCU.

This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Sanofi-Aventis.